Chronic lymphocytic leukaemia / small lymphocytic lymphoma

Overview

Chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) are two manifestations of the same underlying disease: a slow-growing (indolent) cancer of the immune system arising from mature B-lymphocytes. They are classified together as a single entity—CLL/SLL—by the World Health Organization (WHO) and the International Consensus Classification (ICC).

The distinction between the two is purely anatomical, based on where the cancerous cells predominantly accumulate:

• CLL: The malignant cells are found mainly in the blood and bone marrow. By definition, there must be $ge 5 times 10^9/L$ monoclonal B-lymphocytes in the peripheral blood.
• SLL: The malignant cells are found mainly in the lymph nodes and spleen, with a peripheral blood lymphocyte count $< 5 times 10^9/L$.

Despite these different presentations, the cellular biology, genetic drivers, behaviour, and treatment approaches are identical. CLL/SLL is the most common leukaemia in adults in Western countries, accounting for approximately 25–30% of all leukaemias. It is predominantly a disease of older adults, with a median age at diagnosis of 70–72 years. It is rare in individuals under 40 and extremely rare in children.

A diagnosis of CLL or SLL represents the same disease process. The label used depends on where the doctor finds the bulk of the disease at the time of diagnosis. Treatment decisions are based on disease stage, genetic profile, and symptoms—not the label.

Understanding the Disease: Biology and Pathophysiology

The Cell of Origin

CLL/SLL arises from a mature, antigen-experienced B-cell that has undergone malignant transformation. Normal B-cells produce antibodies to fight infection. In CLL/SLL, the malignant clone retains the surface markers of a mature B-cell (CD19, CD20, CD23) but aberrantly expresses CD5 (a T-cell marker) and typically shows dim (weak) expression of surface immunoglobulin (sIg) and CD20.

The Tumour Microenvironment

The survival and proliferation of CLL cells are not autonomous; they are critically dependent on signals from the tumour microenvironment (TME). This includes:

• B-cell Receptor (BCR) Signalling: Chronic stimulation by (auto)antigens drives survival.
• Chemokine/Cytokine Networks: Signals from nurse-like cells, T-cells, and stromal cells in lymph nodes and bone marrow (e.g., CXCL12/CXCR4, BAFF, APRIL) protect cells from apoptosis.
• Immune Dysfunction: Patients have profound immune deficiency (hypogammaglobulinaemia, T-cell exhaustion), leading to infection risk and secondary malignancies.

Aetiology and Risk Factors

The exact cause of the initial genetic mutation remains unknown in most cases. It is a complex interplay of genetic susceptibility and environmental triggers.

Note on MBL: Monoclonal B-cell Lymphocytosis (MBL) is a precursor condition defined by a clonal B-cell population $< 5 times 10^9/L$ without lymphadenopathy or cytopenias. “Low-count MBL” ($< 0.5 times 10^9/L$) is common in the elderly (>5% of >60s) and rarely progresses. “High-count MBL” ($> 0.5 times 10^9/L$) carries a 1–2% per year risk of progression** to CLL requiring treatment.

How Does It Look? (Pathology, Morphology & Immunophenotype)

This section details the microscopic and laboratory “fingerprint” of the disease. Understanding this helps patients interpret their pathology reports.

1. Peripheral Blood Morphology (The “Smudge Cell” Phenomenon)

On a standard peripheral blood smear (Wright-Giemsa stain), the hallmark finding is a lymphocytosis composed of small, mature-looking lymphocytes.

• Nucleus: Dense, clumped chromatin (“soccer ball” or “cracked earth” appearance); inconspicuous nucleoli.
• Cytoplasm: Scant, pale blue, agranular.
• Smudge Cells (Basket Cells): Pathognomonic feature. Because CLL cells are fragile (low cytoskeletal protein vimentin), they rupture during smear preparation, leaving naked, smudged nuclei on the slide. A high percentage of smudge cells correlates with a higher tumour burden and more aggressive biology.
• Prolymphocytes: Larger cells with visible nucleoli and basophilic cytoplasm. $< 15%$ (or $< 55%$ in some classifications) is acceptable for CLL; $ge 15%$ suggests CLL with increased prolymphocytes (a more aggressive variant) or B-cell Prolymphocytic Leukaemia (B-PLL) if $ge 55%$.

2. Bone Marrow Appearance

Bone marrow biopsy is not routinely required for diagnosis (blood flow cytometry suffices) but is performed before certain treatments (e.g., venetoclax ramp-up to assess tumour burden/TLS risk) or to evaluate unexplained cytopenias.

• Infiltration Patterns:
• Nodular: Well-defined round nodules (best prognosis).
• Interstitial: Diffuse infiltration between normal haematopoietic cells.
• Mixed: Combination.
• Diffuse: Sheets of cells replacing normal marrow (worst prognosis, high TLS risk).
• Cellularity: Usually hypercellular due to infiltration; normal haematopoiesis is suppressed in advanced stages.

3. Lymph Node Architecture (SLL Pattern)

In SLL (or CLL with adenopathy), lymph node architecture is effaced by a diffuse proliferation of small lymphocytes.

• Proliferation Centres (Pseudofollicles): Diagnostic hallmark. Clusters of larger cells (prolymphocytes, paraimmunoblasts) within the sea of small cells. These are the sites of active proliferation (Ki-67 high). They are not true follicles (lack follicular dendritic cell meshworks and mantle zones).
• Capsular Invasion: Tumour cells often extend beyond the capsule into perinodal fat.

4. Immunophenotyping (Flow Cytometry) – The Diagnostic Gold Standard

Diagnosis requires flow cytometry on peripheral blood (or tissue) demonstrating a monoclonal B-cell population with the classic CLL/SLL immunophenotype. The Matutes Score (CLL Score) is historically used (score 4–5 = typical CLL).

Atypical CLL (Score 3):** May show stronger sIg, CD20, or FMC7 positivity, or lack CD23. Requires correlation with genetics (FISH) and morphology to rule out Mimics (Mantle Cell, Marginal Zone, Lymphoplasmacytic Lymphoma).

Genetic Landscape: The Prognostic Blueprint

CLL is genetically heterogeneous. Genetic testing (FISH panel + TP53 sequencing + IGHV mutational status) is mandatory before any treatment initiation (iwCLL guidelines).

1. Fluorescence In Situ Hybridisation (FISH) Panel

Detects large chromosomal abnormalities in interphase nuclei. Hierarchy of risk (Döhner Hierarchy):

2. TP53 Mutation (Sequencing)

• ~10–15% of treatment-naive; >30% Relapsed/Refractory (R/R).
• Missense mutations in DNA-binding domain act as “dominant negative.”
• Co-occurrence: del(17p) + TP53 mutation (bi-allelic inactivation) = worst outcome.
• Actionable: Same as del(17p) — Avoid Chemotherapy.

3. IGHV Mutational Status (Somatic Hypermutation)

• Mutated (M-CLL): $ge 2%$ deviation from germline (IGHV identity < 98%). Good Prognosis. Post-germinal centre origin. Subset may never need treatment.
• Unmutated (U-CLL): $< 2%$ deviation (identity $ge 98%$). Poorer Prognosis. Pre-germinal centre/naive B-cell origin. Faster proliferation, shorter Time to First Treatment (TTFT).
• Stereotyped BCR Subsets: ~30% of CLL have near-identical BCRs (e.g., Subset #2 = U-CLL, aggressive; Subset #4 = M-CLL, indolent). Research tool currently.

4. Emerging / Secondary Drivers (NGS Panels)

Next-Generation Sequencing (NGS) identifies mutations driving clonal evolution:

• NOTCH1 (~10–15%): Truncating mutations. Associated with U-CLL, trisomy 12, Richter’s Transformation. Resistance to anti-CD20 antibodies?
• SF3B1 (~10–15%): Splicing factor. Associated with fludarabine resistance, transformation.
• BIRC3 (~4–5%): NF-κB pathway. Associated with fludarabine resistance.
• MYD88 (~3–5%): Associated with M-CLL, good prognosis (overlap with Waldenström’s).
• BTK / PLCG2 Mutations: Acquired Resistance Mutations to BTK inhibitors (C481S in BTK; gain-of-function in PLCG2). Tested at progression on BTKi.

Clinical Presentation: Symptoms

CLL/SLL is frequently asymptomatic at diagnosis (incidental finding on routine CBC in 70–80% of cases). When symptoms occur, they are classified as Disease-Related (B-Symptoms), Mass Effect, Immune Dysregulation, or Complications.

1. Constitutional “B-Symptoms” (Systemic Cytokine Release)

Defined by iwCLL criteria (any one qualifies as “Active Disease” requiring treatment):

• Unintentional Weight Loss: $ge 10%$ body weight in previous 6 months.
• Fevers: $ge 38.0^circtext{C}$ ($ge 100.4^circtext{F}$) for $ge 2$ weeks without evidence of infection.
• Night Sweats: Drenching, requiring change of bedclothes, $ge 1$ episode/week for $ge 1$ month.
• Extreme Fatigue: ECOG Performance Status $ge 2$ (unable to carry out normal activity; up < 50% of day) attributable to CLL (not anaemia/comorbidity).

Mechanism:** Tumour necrosis factor-alpha (TNF-α), IL-6, IL-10, and other cytokines secreted by the malignant clone and microenvironment trigger hypothalamic dysregulation and catabolism.

2. Lymphadenopathy (Mass Effect)

• Pattern: Generalised, symmetrical, painless, rubbery, mobile, non-tender nodes.
• Common Sites: Cervical, axillary, inguinal, supraclavicular.
• Complications:
• Superior Vena Cava (SVC) Syndrome: Mediastinal nodes compress SVC (dyspnoea, facial swelling, distended neck veins) — Medical Emergency.
• Airway Compromise: Tracheal/bronchial compression.
• Ureteric Obstruction: Retroperitoneal nodes $rightarrow$ Hydronephrosis / Renal failure.
• GI Obstruction: Mesenteric nodes.

3. Splenomegaly & Hypersplenism

• Prevalence: 50% at diagnosis; massive in advanced disease.
• Symptoms: Early satiety (gastric compression), Left Upper Quadrant (LUQ) fullness/pain, referred shoulder tip pain (Kehr’s sign – diaphragmatic irritation).
• Hypersplenism: Sequestration $rightarrow$ Thrombocytopenia (platelets $< 100 times 10^9/L$) and/or Anaemia (Hb $< 10$ g/dL) not due to marrow failure. Improves with splenectomy or effective systemic therapy.

4. Immune Dysregulation & Autoimmune Complications (5–10% of patients)

The malignant clone disrupts immune tolerance. These can precede diagnosis or occur during disease course.

• Autoimmune Haemolytic Anaemia (AIHA): Most common (50–70% of autoimmune events). Warm IgG-mediated (DAT+). Hb drops, reticulocytosis, spherocytes, high LDH, low haptoglobin. Direct Coombs Test Positive. Can be refractory; treat CLL + Immunosuppression (Rituximab, Steroids).
• Immune Thrombocytopenia (ITP): Antibody-mediated platelet destruction. Isolated thrombocytopenia, normal/large platelets on smear, megakaryocytes in marrow. DAT Negative. Distinguish from marrow infiltration/hypersplenism.
• Pure Red Cell Aplasia (PRCA): Rare (<1%). T-cell mediated suppression of erythroid precursors. Severe anaemia, reticulocytopenia, absent erythroblasts in marrow.
• Autoimmune Neutropenia / Evans Syndrome: AIHA + ITP simultaneously.

5. Infectious Complications (Leading Cause of Death)

• Hypogammaglobulinaemia: IgG $< 400–500$ mg/dL (or $< 2$ SD below normal) in 60–80% advanced CLL. Impaired opsonization $rightarrow$ Encapsulated bacteria (S. pneumoniae, H. influenzae, Moraxella).
• T-cell Defects: Inverted CD4:CD8 ratio, exhaustion (PD-1 high), impaired viral surveillance $rightarrow$ Herpes Zoster (Shingles) (15–30% lifetime risk), CMV reactivation, COVID-19 severity.
• BTK Inhibitor Effect: Further impairs neutrophil/macrophage function & vaccine responses.
• Venetoclax Effect: Neutropenia (manageable with G-CSF).

6. Second Primary Malignancies (SPMs)

• Risk: 2–3x general population (immune surveillance failure + mutagenic therapy legacy).
• Common: Skin cancers (Melanoma, SCC/BCC – highest relative risk), Lung, Prostate, Breast, Colorectal, Merkel Cell Carcinoma (polyomavirus associated).
• Action: Rigorous annual dermatology screening; age-appropriate cancer screening.

7. Richter’s Transformation (RT)

• Incidence: 2–10% lifetime risk (higher with U-CLL, +12, NOTCH1, TP53 aberrations).
• Histology: Diffuse Large B-Cell Lymphoma (DLBCL) (80–90% – “Clonally Related”) or Hodgkin Lymphoma variant (10–20% – usually EBV+, clonally unrelated).
• Presentation: Rapidly enlarging nodes (often asymmetric, fixed), new B-symptoms (fever, sweats, weight loss), rising LDH, hypercalcaemia, elevated CRP.
• Prognosis: Poor (Median OS ~6–12 months historically). Urgent biopsy mandatory. Treatment: DLBCL-type chemoimmunotherapy (R-CHOP/R-DHAP) $pm$ BTKi bridging $rightarrow$ Allogeneic Stem Cell Transplant (Allo-SCT) if remission achieved.

Staging Systems

Staging determines prognosis and trial eligibility. Staging is clinical (Physical exam + CBC), not radiological (CT not required for staging).

1. Rai Staging System (USA – Clinical)

2. Binet Staging System (Europe – Clinical + Haematological)

Lymphoid Areas: Cervical, Axillary, Inguinal (uni/bi-lateral = 1 area each), Spleen, Liver.

3. Modern Prognostic Indices (Integrating Genetics)

Used for risk stratification in clinical trials and counselling, not for “treating by stage.”

• CLL-IPI (International Prognostic Index): TP53 status, IGHV status, Serum $beta_2$-microglobulin, Clinical Stage, Age. Gold standard for risk grouping.
• Barcelona / MDACC Models: Incorporate complex karyotype, NOTCH1, SF3B1, $beta_2$-M.

Diagnostic Workup Checklist

Mandatory at Diagnosis

1. History & Physical: B-symptoms, infections, autoimmune history, nodal/splenic exam.
2. CBC with Differential: Absolute Lymphocyte Count (ALC), Hb, Platelets.
3. Peripheral Blood Flow Cytometry: Confirm clonality + CLL immunophenotype (Matutes score).
4. Serum Immunoglobulins (IgG, IgA, IgM): Baseline for IVIG decisions.
5. Comprehensive Metabolic Panel (CMP): LDH (baseline for TLS/Richter’s), Uric acid, Creatinine, LFTs.
6. Direct Antiglobulin Test (DAT / Coombs): Baseline for AIHA monitoring.
7. FISH Panel (CLL specific): del(17p), del(11q), Trisomy 12, del(13q).
8. TP53 Sequencing (NGS): Detect mutations without deletion.
9. IGHV Mutational Status: PCR + Sequencing.
10. Hepatitis B (HBsAg, anti-HBc, anti-HBs), Hepatitis C, HIV: Mandatory before immunosuppressive therapy (reactivation risk).
11. Vaccination Status: Administer inactivated vaccines (Pneumococcal, Influenza, COVID-19, RSV, Tdap, Hepatitis B, Shingles recombinant/Shingrix) BEFORE treatment starts. Live vaccines contraindicated.

Situational / Pre-Treatment

• Bone Marrow Biopsy + Aspirate: Before Venetoclax (TLS risk stratification), unexplained cytopenias, suspected transformation.
• CT Neck/Chest/Abdomen/Pelvis: Not for routine staging. Indicated: Bulky nodes (Radiation planning), Suspected SVC syndrome, Organ compression, Clinical Trial requirement.
• Lymph Node Biopsy (Excisional preferred): Suspected Richter’s Transformation, Diagnostic uncertainty (atypical flow).
• Echocardiogram / ECG: Baseline if prior anthracycline exposure or cardiac comorbidities (BTKi atrial fibrillation risk).

Management Philosophy: “Watch and Wait” (Active Surveillance)

> 70% of patients present with early-stage (Rai 0/I/II, Binet A) asymptomatic disease.

Multiple RCTs (CLL1, CLL2, CLL3, ECOG 2997) have proven: Early treatment with chemotherapy or chlorambucil does NOT improve Overall Survival (OS) vs. Active Surveillance.

Active Surveillance Protocol (iwCLL / NCCN / ESMO Guidelines)

Patient Role: You are an active partner. Report changes in energy, infections, lumps, or weight immediately—do not wait for the next scheduled appointment.

Indications for Treatment (iwCLL 2018 / NCCN Criteria)

Asymptomatic early-stage disease is NOT treated. Treatment starts only when Active Disease is documented:

1. Progressive Marrow Failure: Hb $< 10$ g/dL or Platelets $< 100 times 10^9/L$ (due to infiltration/autoimmunity).
2. Massive/Progressive Splenomegaly: > 6 cm below costal margin or symptomatic.
3. Massive/Progressive Lymphadenopathy: $ge 1$ node $> 10$ cm or $ge 3$ nodes $> 5$ cm or symptomatic compression.
4. Constitutional Symptoms (B-Symptoms): Documented weight loss, fevers, night sweats, fatigue (ECOG $ge 2$) attributable to CLL.
5. Autoimmune Cytopenias: AIHA / ITP poorly responsive to steroids/IVIG/rituximab.
6. Progressive Lymphocytosis: Lymphocyte Doubling Time (LDT) $< 6$ months (calculated on $ge 3$ time points over $ge 3$ months). Rarely sole criterion; usually accompanies other features.
7. Richter’s Transformation: Biopsy proven.

Modern Treatment Landscape (Frontline & Relapsed)

PARADIGM SHIFT: Chemoimmunotherapy (CIT: FCR / BR / Chlorambucil+Obinutuzumab) is NO LONGER STANDARD OF CARE for first-line treatment in fit patients (per NCCN/ESMO/iwCLL 2023+ updates). Targeted Novel Agents (BTKi, BCL2i) are Preferred.

Treatment Algorithm Decision Tree

Step 1: Assess Fitness & Genetics

• del(17p) / TP53 mut: Exclude CIT. $rightarrow$ BTKi (Acalabrutinib/Zanubrutinib/Ibrutinib) $pm$ Obinutuzumab OR Venetoclax + Obinutuzumab (Ven-O) (Fixed duration).
• No del(17p)/TP53 mut:
• Fit (CIRS $le 6$, CrCl $ge 30$): Continuous BTKi (Acalabrutinib/Zanubrutinib preferred over Ibrutinib for safety) OR Fixed-Duration Ven-O (12 cycles).
• Unfit / Frail / Comorbid: Ven-O (Fixed Duration) often preferred (finite toxicity, stop after 1 yr) OR BTKi (Continuous).

1. BTK Inhibitors (BTKi) – Continuous Therapy

Target: Bruton Tyrosine Kinase $rightarrow$ Blocks BCR Signalling $rightarrow$ Mobilization from nodes $rightarrow$ Apoptosis.

• Ibrutinib (1st Gen, Irreversible): High efficacy. Toxicity: Atrial Fibrillation (10–15%), Hypertension (20%+), Arthralgia, Diarrhoea, Bleeding (inhibits Tec kinase/GPVI), Infection risk. Drug Interactions: Strong CYP3A4 inhibitors/inducers.
• Acalabrutinib (2nd Gen, Selective, Irreversible): ELEVATE-TN / ASCEND trials. Non-inferior/superior PFS vs Chlorambucil+Obinutuzumab / Ibrutinib. Better Safety: Lower AFib (~5%), HTN, Arthralgia, Diarrhoea. Headache (transient, caffeine helps). PPI Interaction: Avoid PPIs (take with H2 blocker/antacid separation).
• Zanubrutinib (2nd Gen, Selective, Irreversible): SEQUOIA / ALPINE trials. Superior PFS vs Bendamustine-Rituximab (BR) & vs Ibrutinib (R/R). Best Cardiac Safety: Lowest AFib (~2–3%). Dosing: 160mg BID or 320mg QD. No PPI restriction.

BTKi “Lymphocytosis”: Expected. ALC rises sharply (peak 1–3 months) as cells egress from nodes into blood. Not progression.** Nodes shrink. Do not stop drug.

2. BCL-2 Inhibitor – Fixed Duration (Time-Limited)

Venetoclax + Obinutuzumab (Ven-O) – 12 Cycles (1 Year Total)

• Mechanism: Directly inhibits anti-apoptotic BCL-2 $rightarrow$ Rapid apoptosis. High Tumour Lysis Syndrome (TLS) Risk.
• Ramp-Up (5 Weeks): 20 $rightarrow$ 50 $rightarrow$ 100 $rightarrow$ 200 $rightarrow$ 400 mg daily. Mandatory TLS Prophylaxis: Hydration, Allopurinol, Risk-stratified monitoring (Lab TLS vs Clinical TLS).
• Obinutuzumab: Anti-CD20 (Type II, enhanced ADCC). Cycle 1: Day 1, 8, 15 (split dose Day 1/2). Cycles 2–6: Day 1.
• Efficacy (CLL14): Superior PFS vs Chlorambucil+Obinutuzumab. High uMRD rates (Bone Marrow uMRD $sim$ 50–60%). Finite Therapy = Treatment-Free Remission (TFR).
• Toxicity: Neutropenia (50%+ Grade 3/4 – manageable with G-CSF/dose holds), TLS, GI (nausea/diarrhoea), Infection risk (esp. during ramp-up + anti-CD20).
• Stopping Rule: Stop after 12 cycles (1 year) if uMRD achieved; consider continuing if MRD+ (trial dependent).

3. PI3K Inhibitors (Idelalisib, Duvelisib, Umbralisib) – 3rd Line / Niche Use

• Significant Toxicity: Immune-mediated colitis, hepatitis, pneumonitis, infections (PCP prophylaxis mandatory), hyperglycaemia.
• Current Role: Largely replaced by BTKi/Ven/Bi-specifics/CAR-T in guidelines. Used if BTKi + Ven both failed/intolerant.

4. Emerging / Next-Gen Agents (Relapsed/Refractory & Trials)

• Non-Covalent BTK Inhibitors (Pirtobrutinib – JAYPIOR): Binds BTK differently. Active against C481S BTK mutations (resistance to covalent BTKi). BRUIN Trial: High response rates post-covalent BTKi + Ven. FDA Approved (R/R CLL). Low cardiac toxicity.
• BCL-2 / MCL-1 / BFL-1 Inhibitors: Overcoming Ven resistance (MCL-1 upregulation).
• Bispecific Antibodies (Epcoritamab, Mosunetuzamab, Glofitamab): CD3 x CD20. T-cell engagement. High CR/uMRD rates in R/R. CRS / ICANS risk (Step-up dosing).
• CAR-T Cell Therapy (Lisocabtagene maraleucel / Brexucabtagene): TRANSCEND / ZUMA-8 Trials. High CR/uMRD in high-risk R/R (post-BTKi+Ven). Manufacturing time / Cost / Toxicity (CRS/ICANS) barriers.
• Allogeneic Stem Cell Transplant (Allo-SCT): Only potentially curative modality. Reserved for: Richter’s Transformation (in CR), High-risk R/R (Complex Karyotype, BTKi+Ven failure), Young/Fit patients with donor. Non-Myeloablative (RIC) conditioning standard. GVHD risk vs Graft-vs-Leukaemia benefit.

Supportive Care: Essential for Quality of Life

Special Clinical Scenarios

1. CLL and Pregnancy

• Rare. Most diagnosed > 50.
• Diagnosis: Flow cytometry safe. FISH safe. Avoid CT (Radiation). MRI (no contrast) preferred for staging if needed.
• Treatment: Watch & Wait preferred. If treatment mandatory (aggressive disease):
• 2nd/3rd Trimester: Rituximab (crosses placenta late 2nd tri $rightarrow$ B-cell depletion in neonate $rightarrow$ monitor vaccines/IVIG). Steroids (Dexamethasone/Prednisolone – low placental transfer).
• CONTRAINDICATED: BTKi (Teratogenic in animals), Venetoclax (Teratogenic), Chemotherapy (Fludarabine/Bendamustine – teratogenic), PI3Ki.
• Delivery: Vaginal delivery preferred. Neonate: Check B-cells, IgG; delay live vaccines.

2. CLL with Chronic Kidney Disease (CKD)

• Venetoclax: Dose adjustment NOT required for mild/mod renal impairment. Avoid/Reduce in Severe (CrCl $< 15$ / Dialysis) – limited data, use with extreme caution/intensive TLS monitoring.
• BTKi: No renal dose adjustment (hepatic metabolism). Preferred in severe CKD/ESRD.
• Obinutuzumab/Rituximab: No renal dose adjustment.
• Contrast: Avoid IV contrast for CT if possible (MRI alternative) to preserve renal function.

3. Richter’s Transformation (RT) – Detailed Management

1. Confirm: Excisional Biopsy + FISH/NGS (Clonality vs TP53/MYC/BCL2/BCL6 “Double/Triple Hit”).
2. Stage: PET-CT (Standard for DLBCL).
3. Treat: R-CHOP x 6 or R-DHAP / R-ICE (if high bulk/renal issues) $pm$ BTKi continuation (data suggests benefit).
4. Consolidate: Allo-SCT (RIC) in First Complete Remission (CR1) is standard for eligible patients (Age $< 70–75$, HCT-CI low, Donor available). Auto-SCT NOT recommended (high relapse from contaminated graft/residual host immunity).
5. Hodgkin Variant: ABVD $pm$ Rituximab $rightarrow$ Allo-SCT if refractory/relapsed.

Prognosis and Survivorship

Survival Statistics (Modern Era Context)

• Median Overall Survival (OS): Not reached in many modern frontline trials (CLL14, ELEVATE-TN, SEQUOIA, ALLIANCE) with >5–7 year follow-up.
• 10-Year OS: > 80% for fit patients without del(17p)/TP53 mut on novel agents.
• del(17p)/TP53 mut: Median OS significantly improved with BTKi (Ibrutinib: ~8–10 yrs; Acalabrutinib/Zanubrutinib: not reached at 5+ yrs) vs historical chemo (< 3 yrs).
• Cause of Death: Infections (30–40%), Second Cancers (15–20%), Richter’s (10–15%), Cardiovascular/Comorbidities.

Survivorship Care Plan (Long-Term Follow-Up)

1. Disease Monitoring: CBC q3–6mo indefinitely. Flow cytometry for MRD if clinically indicated (rising counts).
2. Cardiovascular Health: Aggressive risk factor modification (Statins, BP control, Weight, Exercise). Cardio-Oncology referral if on BTKi long-term.
3. Bone Health: Baseline DEXA. Vitamin D/Calcium. Bisphosphonates/Denosumab if osteopenia/osteoporosis (Steroids/CLL increase fracture risk).
4. Mental Health: Anxiety, “Scanxiety,” Fear of Progression, Cognitive effects (“Chemo brain” / “BTKi brain”). Psycho-oncology referral.
5. Financial Toxicity: Oral oncolytics (BTKi) = High co-pays. Social Work / Foundation Assistance (LLS, PAN, Patient Advocate Foundation, Manufacturer Copay Cards).
6. Advance Care Planning: Goals of care discussions early, revisited at progression.

Patient-Centric Practical Guide: Living Well with CLL/SLL

The “New Normal” Checklist

• [ ] Build Your Team: Haematologist/Oncologist (CLL Specialist preferred), Primary Care, Cardiologist, Dermatologist, Infectious Disease (if complex), Pharmacist (Specialty Pharmacy Liaison).
• [ ] Organise Records: Keep a personal health binder/app with: Diagnostic reports (Flow, FISH, IGHV), Treatment summaries, Medication list (incl. doses/schedule), Vaccination card, Insurance authorizations.
• [ ] Medication Adherence (BTKi): Take daily, same time. Missed dose? Take ASAP if $< 12$ hrs late; skip if $> 12$ hrs. Do NOT double dose. Use pill box / App reminders.
• [ ] Drug Interaction Vigilance: Check EVERY new prescription/OTC/Supplement with CLL Pharmacist/Team. Key Interactions: Strong CYP3A4 Inhibitors (Azole antifungals, Clarithromycin, Grapefruit/Seville orange) $uparrow$ BTKi levels $rightarrow$ Toxicity. Strong Inducers (Carbamazepine, Phenytoin, Rifampin, St. John’s Wort) $downarrow$ BTKi levels $rightarrow$ Resistance. PPIs $downarrow$ Acalabrutinib absorption.
• [ ] Infection Prevention: Hand hygiene. Mask in crowds/healthcare (post-COVID norm). Avoid raw/undercooked food (sushi, rare meat, unpasteurized cheese) if neutropenic/IgG low. Dental hygiene (brush/floss) $rightarrow$ prevent bacteremia.
• [ ] Skin Surveillance: Monthly self-skin exam. Annual Dermatologist. Sunscreen (SPF 30+), Hats, UPF clothing. Report new/changing lesions immediately.
• [ ] Fatigue Management: Graded Exercise Therapy (Walking, Resistance bands). Sleep hygiene. Treat anaemia/thyroid/depression/sleep apnoea. Pacing activities.
• [ ] Nutrition: Mediterranean / Plant-forward diet. Adequate protein (1.0–1.2 g/kg) for muscle maintenance. Hydration (2–3L/day, critical on Ven ramp-up). Limit Alcohol (Liver metabolism of BTKi).
• [ ] Travel: Carry Medication in Carry-On (original bottles + Doctor’s letter). Time zone adjustments for BTKi (keep ~24h interval). Travel insurance covering pre-existing conditions. Know local hospital locations. Blood products abroad MUST be irradiated.

Glossary of Key Terms

Frequently Asked Questions (FAQ)

Q: “I have been diagnosed with CLL but my doctor says ‘Watch and Wait’. Isn’t that neglecting my cancer?”

A: Absolutely not. This is evidence-based standard of care. Multiple large randomized trials proved that treating early-stage asymptomatic CLL with chemotherapy does not help you live longer but does cause side effects (infections, second cancers, neuropathy) and reduces quality of life unnecessarily. “Active Surveillance” means active monitoring—you are followed closely so treatment starts the moment it provides benefit. Early treatment is currently only offered in clinical trials testing if novel agents can cure early disease (which is not yet proven).

Q: “Will I lose my hair on these new treatments?”

A: No. BTK inhibitors (Ibrutinib, Acalabrutinib, Zanubrutinib, Pirtobrutinib) and Venetoclax do not cause alopecia (hair loss). This is a major quality-of-life advantage over traditional chemotherapy.

Q: “Can I stop my BTK inhibitor if I feel fine / my counts are normal?”

A: Generally, NO. BTKi are continuous, indefinite therapies. Stopping leads to rapid disease flare (lymphocytosis, node regrowth, symptom return) in the vast majority of patients within months. Only stop on your haematologist’s explicit instruction (e.g., for major surgery, uncontrolled toxicity, or enrolment in a specific “fixed-duration” clinical trial). Venetoclax + Obinutuzumab IS a fixed 1-year course designed to stop.

Q: “I have del(17p). Does that mean I am terminal?”

A: No. Historically, del(17p)/TP53 mutation meant very poor outcomes with chemotherapy (median survival 2–3 years). With modern BTK inhibitors (Acalabrutinib, Zanubrutinib, Ibrutinib) or Venetoclax-based regimens, outcomes have dramatically improved. Median survival is now measured in many years (often >10 years), and many patients live a near-normal lifespan. It changes which treatment you get, not if you can be treated effectively.

Q: “Do I need a bone marrow biopsy?”

A: Not for routine diagnosis. Blood flow cytometry + FISH is sufficient. A biopsy is needed: 1) Before starting Venetoclax (to assess TLS risk), 2) If blood counts drop inexplicably (marrow failure vs hypersplenism vs autoimmune), 3) If Richter’s Transformation is suspected, 4) For clinical trials.

Q: “Can I take supplements like Green Tea Extract (EGCG), Curcumin, or CBD Oil?”

A: Discuss with your team FIRST.

• EGCG: Early phase trials showed some activity but high doses cause liver toxicity; interacts with BTKi metabolism (CYP3A4). Not standard care.
• Curcumin: Poor bioavailability; theoretical interaction with CYP enzymes.
• CBD Oil: Strong CYP3A4 Inhibitor $rightarrow$ Increases BTKi levels $rightarrow$ Toxicity Risk. Also liver enzyme elevation risk.
• St. John’s Wort: Strong CYP3A4 Inducer $rightarrow$ Destroys BTKi efficacy $rightarrow$ Resistance. STRICTLY AVOID.

Q: “Is CLL hereditary? Should my children be tested?”

A: There is a familial clustering (2–7x risk for 1st degree relatives), but no single “CLL gene” is inherited in a Mendelian fashion. It is polygenic susceptibility + environment. Routine screening of asymptomatic relatives is NOT recommended (no proven benefit, causes anxiety, insurance implications). Relatives should have standard age-appropriate check-ups and mention family history to their GP.

References

• Guidelines & Consensus Reports
• Eichhorst, B. et al. (2023) ‘Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(1), pp. 28–47. doi:10.1016/j.annonc.2022.09.011.
• National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Version 2.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf (Accessed: [Current Date]).
• Hallek, M. et al. (2018) ‘iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL’, Blood, 131(25), pp. 2745–2760. doi:10.1182/blood-2017-09-806398.
• Strati, P. et al. (2023) ‘International Workshop on CLL (iwCLL) updated recommendations’, Blood, 142(12), pp. 1013–1028.
• Landmark Clinical Trials (Frontline)
• Fischer, K. et al. (2019) ‘Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (CLL14)’, New England Journal of Medicine, 380(24), pp. 2225–2236. doi:10.1056/NEJMoa1815281.
• Sharman, J.P. et al. (2020) ‘Acalabrutinib with or without Obinutuzumab vs Chlorambucil and Obinutuzumab in Treatment-Naive CLL (ELEVATE-TN)’, Journal of Clinical Oncology, 38(27), pp. 3123–3133. doi:10.1200/JCO.20.00179.
• Mai, E.K. et al. (2023) ‘Zanubrutinib vs Bendamustine-Rituximab in Treatment-Naive CLL (SEQUOIA)’, New England Journal of Medicine, 388(4), pp. 319–332. doi:10.1056/NEJMoa2208451.
• Brown, J.R. et al. (2023) ‘Pirtobrutinib in Covalent BTK Inhibitor–Pretreated CLL (BRUIN)’, New England Journal of Medicine, 388(4), pp. 333–343. doi:10.1056/NEJMoa2208450. (For non-covalent BTKi context).
• Prognostics & Genetics
• International CLL-IPI Working Group (2016) ‘An International Prognostic Index for CLL (CLL-IPI)’, Blood, 127(21), pp. 2589–2599. doi:10.1182/blood-2016-01-697085.
• Döhner, H. et al. (2000) ‘Genomic Aberrations and Survival in CLL’, New England Journal of Medicine, 343(26), pp. 1910–1916. (Classic Hierarchy).
• Puente, X.S. et al. (2015) ‘Non-coding mutations in CLL’, Nature, 526, pp. 519–524. (Driver mutations).
• Landau, D.A. et al. (2015) ‘Clonal Evolution in CLL’, Nature, 526, pp. 525–530.
• Richter’s Transformation & High Risk
• Rossi, D. et al. (2021) ‘Clinical and Molecular Features of Richter Syndrome’, Blood, 138(10), pp. 829–842.
• Parry, H.M. et al. (2021) ‘Outcomes of Allogeneic Transplant for Richter Syndrome’, Journal of Clinical Oncology, 39(15), pp. 1664–1674.
• Supportive Care & Infections
• Shadman, M. et al. (2021) ‘Infectious Complications in CLL in the Era of Novel Agents’, Leukemia, 35, pp. 2875–2889.
• Mato, A.R. et al. (2018) ‘Toxicities of BTK and BCL2 Inhibitors’, Blood, 132(24), pp. 2591–2600.
• National Institute for Health and Care Excellence (NICE) (2023) Venetoclax with Obinutuzumab for Untreated CLL. Technology Appraisal Guidance [TA760].
• Patient Advocacy & Education Resources
• CLL Society: https://cllsociety.org/ (Physician-curated, patient-focused education, toolkits, specialist finder).
• Leukemia & Lymphoma Society (LLS): https://www.lls.org/ (Free information specialists, financial aid, clinical trial support).
• Lymphoma Research Foundation (LRF): https://lymphoma.org/ (Helpline, webinars, fact sheets).
• Patient Power: https://www.patientpower.info/ (Interviews with CLL experts, patient stories).
• ClinicalTrials.gov: https://clinicaltrials.gov/ (Search “CLL” + “Location” for trial options).

Disclaimer